News & Events about Codexis Inc.
Codexis, Inc. (NASDAQ:CDXS Get Rating) Director John J. Nicols sold 35,714 shares of the firms stock in a transaction dated Tuesday, April 18th. The stock was sold at an average price of $4.14, for a total transaction of $147,855.96. Following the completion of the transaction, the director now owns...
Simply Wall St
8 months ago
It's not a secret that every investor will make bad investments, from time to time. But it should be a priority to...
Ticker Report
9 months ago
Skandinaviska Enskilda Banken AB publ cut its stake in Codexis, Inc. (NASDAQ:CDXS Get Rating) by 23.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,375 shares of the biotechnology ...
Globe Newswire
11 months ago
Collaboration with Merck published in Science magazine REDWOOD CITY, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announces the publication with Merck, known as MSD outside the United ...
Ticker Report
12 months ago
Qube Research Technologies Ltd reduced its position in Codexis, Inc. (NASDAQ:CDXS Get Rating) by 32.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,827 shares of the biotechnology companys stock after selling ...